What is Leucid Bio?
Leucid Bio operates at the intersection of synthetic biology and oncology, leveraging a proprietary engine to engineer chimeric antigen receptor T cell (CAR T) therapies. Unlike conventional approaches that often struggle with the immunosuppressive microenvironment of solid tumors, Leucid Bio utilizes its unique technological framework to enhance the persistence and efficacy of its cell-based products. Based in the United Kingdom, the company has established itself as a pivotal player in the European life sciences ecosystem, focusing on precision medicine and the development of novel therapeutic candidates that offer hope to patients who have exhausted standard treatment options. Their market position is defined by a rigorous scientific approach to overcoming the biological barriers inherent in solid tumor treatment.
How much funding has Leucid Bio raised?
Leucid Bio has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2021): $16M with participation from Future Fund, 2Invest, Epidarex Capital, and Vulpes Investment Management
Key Investors in Leucid Bio
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs. The firm is led by a diverse team of early-stage investors who act as trusted partners to founders and co-investors.
Vulpes Investment Management
Vulpes Investment is an opportunistic alternative investment manager focused on long-term value creation and aligning incentives with investors. The company operates with a family office structure, concentrating on a select number of compelling investment strategies across various sectors, including life sciences.
Future Fund
Future Fund was established in 2006 to invest for the benefit of future generations of Australians. By helping to meet unfunded public sector superannuation liabilities, it supports long-term financial stability and strategic growth initiatives.
What's next for Leucid Bio?
With the successful closure of this major strategic investment, Leucid Bio is poised to transition into a more intensive phase of clinical validation. The capital will likely be deployed to expand the company's internal research capabilities, scale manufacturing processes for its CAR T pipeline, and initiate or advance ongoing clinical trials. As the firm moves deeper into its lifecycle, the focus will shift toward demonstrating safety and efficacy in human subjects, which is essential for future regulatory approval and potential commercialization. The involvement of sophisticated institutional backers suggests a long-term growth trajectory aimed at establishing Leucid Bio as a cornerstone of the next generation of oncology therapeutics, potentially setting the stage for future partnerships or strategic exits within the global biopharmaceutical landscape.
See full Leucid Bio company page
